Earnings Releases·Nov 9, 2026, 4:10 PM ET

GeneDx — Third Quarter 2026 Earnings Summary

Q3 2026 revenue rose 5% year-over-year to $123.1 million, driven by a 25% volume increase in exome and genome tests to 32,134, though adjusted net income declined to $8.6 million from $16.1 million in Q3 2025.
Full-year 2026 revenue guidance remains unchanged at $475–$490 million, while volume and revenue growth targets were lowered to at least 28% and 17% respectively, with adjusted net income guidance revised to approximately $12 million.
Long-term debt increased significantly to $146.2 million as of September 30, 2026, following the issuance of $146.0 million in proceeds and the repayment of $54.0 million to Perceptive.
Strategic expansion includes the launch of long-read whole genome sequencing, new sponsored testing programs with Mirum and Beren Therapeutics, and Medicaid coverage for whole genome sequencing in 25 states.